FORXIGA® (dapagliflozin)

FORXIGA® (dapagliflozin) is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1

Benefits of treatment with FORXIGA® (dapagliflozin)

Patient profiles

FORXIGA® patient profiles
FORXIGA® patient profiles

The most widely prescribed SGLT2i in the UK13 Since 2012, FORXIGA® (dapagliflozin) has been starting change for everyday patients, including those with:

- A recent diagnosis of type 2 diabetes
- Uncontrolled HbA1c, despite treatment with metformin
- Normal renal function

Prescribed in over 100,000 patients in the UK
Prescribed in over 100,000 patients in the UK

 

How could FORXIGA® (dapagliflozin) help your patients?

In post-hoc analyses of phase 3 randomized controlled trials (RCTs), FORXIGA® (dapagliflozin) demonstrated:

- Greater HbA1c reductions than saxagliptin, a DPP-4i30
- The secondary benefit of weight loss, proportional to patient BMI 1,4

FORXIGA® (dapagliflozin) also provides simple dosing for both you and your patients 1

With Real-World Evidence in support of clinical trial data, start treatment with FORXIGA® (dapagliflozin) 10 mg: glucose control without the need for titration1*

Click here to find out more about how FORXIGA®(dapagliflozin) might benefit your patients ahead of a DPP-4i

 *In patients with severe hepatic impairment, a starting dose of 5 mg is recommended. 

FORXIGA® (dapagliflozin) delivers sustained reductions in HbA1c

FORXIGA® (dapagliflozin) delivers sustained reductions in HbA1c vs placebo over 102 weeks when stepping up from metformin5

At 24 week primary endpoint, FORXIGA® delivered HbA1c reductions of –0.8% versus –0.3% with placebo (p<0.0001).5

Reductions in HbA1C with FORXIGA® + metformin vs placebo + metformin over 102 weeks
Reductions in HbA1C with FORXIGA® + metformin vs placebo + metformin over 102 weeks

Adapted from Bailey at al 2013

FORXIGA® (dapagliflozin) 10 mg also demonstrated significant HbA1C reductions in patients with high baseline when given in addition to metformin6

Significant reduction in HbA1c vs placebo at 24 weeks6*

Patients with baseline HbA1c > 9%: Prespecified Secondary endpoint 

Reduction in HbA1C with FORXIGA® + metformin vs placebo at 24 weeks in patients with high baselines
Reduction in HbA1C with FORXIGA® + metformin vs placebo at 24 weeks in patients with high baselines

RCT, randomised controlled trial; DPP-4i, dipeptidyl peptidase-4 inhibitor; BMI, body mass index.

*Changes reported for week 24 are adjusted for baseline values and are based on last observation carried forward (LOCF). The primary efficacy dataset consisted of all randomised patients who received at least one dose of double-blind study medication and who had both a baseline and at least one post-baseline measurement. Mean baseline HbA1c levels for the overall trial population were, 8.11% (65 mmol/mol) for the placebo arm and 7.92% (63 mmol/mol) for the FORXIGA® arm.6